ReviewThe Journal of clinical investigation2021
How elite controllers and posttreatment controllers inform our search for an HIV-1 cure.
Review in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.Frontiers in immunology · 2024Trial
- The HIV reservoir landscape in elite controllers.Current opinion in HIV and AIDS · 2026Review
- Characterization of elite controllers with an undetectable intact HIV DNA reservoir.The Journal of clinical investigation · 2026Article
- CD8Nature · 2026Article
- Shaping the founders: naïve CD4 T cell heterogeneity in people with HIV-1 or HIV-2.Frontiers in immunology · 2026Article
- Learning from nature: HIV elite controllers as blueprints for a functional cure.Virology journal · 2025Review
- The promise and perils of humanized mice: workshop report from the 29th scientific conference of the society on NeuroImmune pharmacology (SNIP).NeuroImmune pharmacology and therapeutics · 2025Article
- From network biology to immunity: potential longitudinal biomarkers for targeting the network topology of the HIV reservoir.Journal of translational medicine · 2025Review
- Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV.Drug delivery and translational research · 2025Review
- Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection.Current opinion in HIV and AIDS · 2025Review
- The utility of nonhuman primate models for understanding acute HIV-1 infection.Current opinion in HIV and AIDS · 2025Review
- The Complex Interactions Between HIV-1 and Human Host Cell Genome: From Molecular Mechanisms to Clinical Practice.International journal of molecular sciences · 2025Review
- HIV-1 Rebound Virus Consists of a Small Number of Lineages That Entered the Reservoir Close to ART Initiation.bioRxiv : the preprint server for biology · 2025Article
- HIV controllers: hope for a functional cure.Frontiers in immunology · 2025Review
- The impact of sex on HIV immunopathogenesis and therapeutic interventions.The Journal of clinical investigation · 2024Review
- Survival Analysis and Immune Differences of HIV Long-Term Non-progressors in Xinjiang China: A 12-Year Prospective Cohort Observation.AIDS and behavior · 2024Observational
- Modelling HIV-1 control and remission.NPJ systems biology and applications · 2024Review
- Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1-infected T cell clones.The Journal of clinical investigation · 2023Article
- CD8+ cells and small viral reservoirs facilitate post-ART control of SIV replication in M3+ Mauritian cynomolgus macaques initiated on ART two weeks post-infection.PLoS pathogens · 2023Article
- HIV infection.Nature reviews. Disease primers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A small percentage of people living with HIV-1 can control viral replication without antiretroviral therapy (ART). These patients are called elite controllers (ECs) if they are able to maintain viral suppression without initiating ART and posttreatment controllers (PTCs) if they control HIV replication after ART has been discontinued. Both types of controllers may serve as a model of a functional cure for HIV-1 but the mechanisms responsible for viral control have not been fully elucidated. In this review, we highlight key lessons that have been learned so far in the study of ECs and PTCs and their implications for HIV cure research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.